000			01509 a2200421 4500
005			20250517132210.0
264		0	_c20170815
008			201708s 0 0 eng d
022			_a1528-0020
024	7		_a10.1182/blood-2016-10-695965 _2doi
040			_aNLM _beng _cNLM
100	1		_aVannucchi, Alessandro M
245	0	0	_aEmerging treatments for classical myeloproliferative neoplasms. _h[electronic resource]
260			_bBlood _c02 2017
300			_a693-703 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aClinical Trials as Topic
650	0	4	_aDisease Progression
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHistone Deacetylase Inhibitors _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aJanus Kinase 2 _xantagonists & inhibitors
650	0	4	_aMutation
650	0	4	_aNitriles
650	0	4	_aPolycythemia Vera _xdrug therapy
650	0	4	_aPrimary Myelofibrosis _xdrug therapy
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aPyrazoles _xtherapeutic use
650	0	4	_aPyrimidines
650	0	4	_aQuality of Life
650	0	4	_aSurvival Analysis
650	0	4	_aThrombocythemia, Essential _xdrug therapy
700	1		_aHarrison, Claire N
773	0		_tBlood _gvol. 129 _gno. 6 _gp. 693-703
856	4	0	_uhttps://doi.org/10.1182/blood-2016-10-695965 _zAvailable from publisher's website
999			_c26735554 _d26735554